Seminars in Fetal & Neonatal Medicine
Volume 15, Issue 5 , Pages 293-298 , October 2010

Synergistic neuroprotective therapies with hypothermia

  • Maria Roberta Cilio

      Affiliations

    • Newborn Brain Research Institute, University of California, San Francisco, California, USA
    • Division of Neurology, Bambino Gesú Children's Hospital, Rome, Italy
    • ,
  • Donna M. Ferriero

      Affiliations

    • Newborn Brain Research Institute, University of California, San Francisco, California, USA
    • Corresponding Author InformationCorresponding author. University of California San Francisco, Department of Neurology, Box 0663, 521 Parnassus Avenue C215, San Francisco, CA 94143-0663, USA. Tel.: +1 415 502 1099; fax: +1 415 502 5821.

References 

  1. Hagberg B, Hagberg G. The changing panorama of cerebral palsy – bilateral spastic forms in particular. Acta Paediatr. 1996;416:48–52
  2. Gunn AJ. Cerebral hypothermia for prevention of brain injury following perinatal asphyxia. Curr Opin Pediatr. 2000;12:111
  3. Kapetanakis A, Azzopardi D, Wyatt J, Robertson NJ. Therapeutic hypothermia for neonatal encephalopathy: a UK survey of opinion, practice and neuro-investigation at the end of 2007. Acta Paediatr. 2009;98:631–635
  4. Azzopardi D, Strohm B, Edwards AD, et al. Steering Group and TOBY Cooling Register Participants Arch Dis Child Fetal Neonatal Ed. 2009;94:F260–F264
  5. Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomized trial. Lancet. 2005;365:663–670
  6. Shankaran S, Laptook AR, Ehrenkrantz RA, et al. Whole-body hypothermia for neonates with hypoxic–ischemic encephalopathy. N Engl J Med. 2005;353:1574–1584
  7. Azzopardi DV, Strohm B, Edwards AD, et al. TOBY Study Group Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009;361:1349–1358
  8. Gunn AJ, Thoresen M. Hypothermic neuroprotection. NeuroRx. 2006;3:154–169
  9. Gunn AJ, Wyatt JS, Whitelaw A, et al. CoolCap Study Group Therapeutic hypothermia changes the prognostic value of clinical evaluation of neonatal encephalopathy. J Pediatr. 2008;152:55–58
  10. Shankaran S, Pappas A, Laptook AR, et al. NICHD Neonatal Research Network Outcomes of safety and effectiveness in a multicenter randomized, controlled trial of whole-body hypothermia for neonatal hypoxic-ischemic encephalopathy. Pediatrics. 2008;122:e791–8
  11. Wyatt JS, Gluckman PD, Liu PY, et al. CoolCap Study Group Pediatrics. 2007;119:912–921
  12. Roka A, Melinda KT, Vasarhelyi B, Machay T, Azzopardi D, Szabo M. Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy. Pediatrics. 2008;121:e844–9
  13. Aicardi J. Overview: neonatal seizures. In:  Engel JJ,  Pedley TA editor. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott Williams & Wilkins; 2008;p. 2283–2285
  14. Calabresi P, Cupini LM, Centonze D, Pisani F, Bernardi G. Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann Neurol. 2003;53:693–703
  15. Liu Y, Barks JD, Xu G, Silverstein FS. Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats. Stroke. 2004;35:1460–1465
  16. Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia. 2000;41:S52–60
  17. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhaces GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997;28:167–179
  18. Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett. 1997;231:123–126
  19. Herrero AI, Del Olmo N, Gonzáles-Escalada JR, Solís JM. The two new actions of topiramate: inhibition of depolarizing GABA (A)-mediated responses and activation of a potassium conductance. Neuropharmacology. 2002;42:210–220
  20. Noh MR, Kim SK, Sun W, et al. Neuroprotective effect of topiramate on hypoxic ischemic injury in neonatal rats. Exp Neurol. 2006;210:470–478
  21. Angehagen M, Rönnbäck L, Hansson E, Ben-Menachem E. Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorilation in astrocytes from primary cultures. J Neurochem. 2005;94:1124–1130
  22. Follet PL, Deng W, Dai W, et al. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J Neurosci. 2004;24:4412–4420
  23. Schubert S, Brandl U, Brodhun M, et al. Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets. Brain Res. 2005;1058:129–136
  24. Filippi L, la Marca G, Fiorini P, et al. Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic-ischemic encephalopathy. Epilepsia. 2009;50:2355–2361
  25. Glauser TA, Miles MV, Tang P, Clark P, McGee K, Doose DR. Topiramate pharmacokinetics in infants. Epilepsia. 1999;40:788–791
  26. Kim J, Kondratyev A, Gale K. Antiepileptic drug-indiced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy versus polytherapy. J Pharmacol Exp Ther. 2007;323:165–173
  27. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101:9861–9866
  28. Lee CY, Chen CC, Liou HH. Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus. Br J Pharmacol. 2009;158:1753–1762
  29. Mazarati AM, Baldwin R, Klitgaard H, Matagne A, Wasterlain CG. Anticonvulsant effects of levetiracetam and levetiracetam–diazepam combinations in experimental status epilepticus. Epilepsy Res. 2004;58:167–174
  30. Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure. 2001;10:287–293
  31. Costa C, Martella G, Picconi B, et al. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke. 2006;37:1319–1326
  32. Kim JS, Kondratyev A, Tomita Y, Gale K. Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. Epilepsia. 2007;48:19–26
  33. Shoemaker MT, Rotemberg JS. Levetiracetam for the treatment of neonatal seizures. J Child Neurol. 2007;22:95–98
  34. Piña-Garza JE, Nordli DR, Rating D, Yang H, Schiemann-Delgado J, Duncan B. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia. 2009;50:1141–1149
  35. Dworschak M . Pharmacologic neuroprotection. Is xenon the light at the end of the tunnel?. Crit Care Med. 2008;36:2477–2478
  36. Istaphanous GK, Loepke AW. General anesthetics and the developing brain. Curr Opin Anaesthesiol. 2009;22:368–373
  37. Dinse A, Fohr KJ, Geogieff M, Beyer C, Bulling A, Weight HU. Xenon reduces glutamate-, AMPA-, and kainate-induced membrane currents in cortical neurons. Br J Anaesth. 2005;94:479–485
  38. Gruss M, Bushell TJ, Bright DP, Lieb WR, Mathie A, Franks NP. Two-pore-domain K+ channels are novel target for the anesthetic gases xenon, nitrous oxyde, and cyclopropane. Mol Pharmacol. 2004;65:443–452
  39. Goto T, Matsukawa T, Sessler DI, et al. Thermoregulatory threshold for vasoconstriction in patients anesthetized with various 1-minimum alveolar concentration combinations of xenon, nitrous oxide, and isoflurane. Anesthesiology. 1999;91:626–632
  40. David NH, Haelewyn B, Rouillon C, et al. Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. FASEB J. 2008;22:1275–1286
  41. Ma D, Hossain M, Chow A, et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann Neurol. 2005;58:182–193
  42. Hobbs C, Thoresen M, Tucker A, Aquilina K, Chakkarapani E, Dingley J. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke. 2008;39:1307–1313
  43. Thoresen M, Hobbs CE, Wood T, Chakkarapani E, Dingley J. Cooling combined with immediate or delayed xenon inhalation provides equivalent long-term neuroprotection after neonatal hypoxia–ischemia. J Cereb Blood Flow Metab. 2009;29:704–714
  44. Khan M, Sekhon B, Jatana M, et al. Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. J Neurosci Res. 2004;76:519–527
  45. Jatana M, Singh I, Singh AK, Jenkins D. Combination of systemic hypothermia and N-acetylcysteine attenuates hypoxic–ischemic brain injury in neonatal rats. Pediatr Res. 2006;59:684–689
  46. Cakir O, Erdem K, Oruc A, Kilinc N, Eren N. Neuroprotective effect of N-acetylcysteine and hypothermia on the spinal cord ischemia–reperfusion injury. Cardiovasc Surg. 2003;11:375–379
  47. Paintlia MK, Paintlia AS, Barbosa E, Singh I, Singh AK. N-Acetylcysteine prevents endotoxin-induced degeneration of oligodendrocyte progenitors and hypomyelination in developing rat brain. J Neurosci Res. 2004;78:347–361
  48. Ahola T, Fellman V, Laaksonen R, et al. Pharmacokinetics of intravenous N-acetylcysteine in pre-term new-born infants. Eur J Clin Pharmacol. 1999;55:645–650
  49. Ahola T, Lapatto R, Raivio KO, et al. N-Acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. J Pediatr. 2003;143:713–719
  50. Maier RF, Obladen M, Scigalla P, et al. For the European Multicentre Erythropoietin Study Group The need of Epoetin Beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. N Engl J Med. 1994;330:1173–1178
  51. Ohls RK, Ehrenkranz RA, Das A, et al. National Institute of Child Health and Human Development Neonatal Research network Neurodevelopmental outcome and growth at 18 and 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics. 2004;114:1287–1291
  52. Maiese K, Li F, Chong ZZ. New avenues of explorations for erythropoietin. J Am Med Assoc. 2005;293:90–95
  53. Kellert BA, McPherson RJ, Juul SE. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res. 2007;61:451–455
  54. Gonzalez FF, McQuillen P, Mu D, et al. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci. 2007;29:321–330
  55. Gonzalez FF, Abel R, Almli CR, Mu D, Wendland M, Ferriero DM. Erythropoietin sustains cognitive function and brain volume after neonatal stroke. Dev Neurosci. 2009;31:403–411
  56. van der Kooij MA, Groenendaal F, Kavelaars A, Heijnen CJ, van Bel F. Combination of deferoxamine and erythropoietin: therapy for hypoxia–ischemia-induced brain injury in the neonatal rat?. Neurosci Lett. 2009;451:109–113
  57. Zhu C, Kang W, Xy F, et al. Erythropoietin improved neurological outcomes in newborns with hypoxic–ischemic encephalopathy. Pediatrics. 2009;124:e218–26
  58. Cariou A, Claessens Y-E, Pène F, et al. Early high dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: a matched control study. Resuscitation. 2008;76:397–404
  59. Ehrenreich H, Weissenborn K, Prange H, et al. For the EPO Stroke Trial Group Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. Oct 15 2009;40:[Epub ahead of print]
  60. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocrine J. 1993;1:57–60
  61. Ashrafi MR, Mohammadi M, Tafarroji J, Shabanian R, Salamati P, Zamani GR. Melatonin versus chloral hydrate for recording sleep EEG. Eur J Paediatr Neurol. Jul 17 2009;[Epub ahead of print]
  62. Husson I, Mesplès B, Bac P, Vamecq J, Evrard P, Gressens P. Melatoninergic neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge. Ann Neurol. 2002;51:82–92
  63. Bouslama M, Renaud J, Olivier P, et al. Melatonin prevents learning disorders in brain-lesioned newborn mice. Neuroscience. 2007;150:712–719
  64. Carloni S, Perrone S, Buonocore G, Longini M, Proietti F, Balduini W. Melatonin protects from the long-term consequences of a neonatal hypoxic–ischemic brain injury in rats. J Pineal Res. 2008;44:157–164
  65. Ronen RL, Gai N, Mechoulam R, Ovadia H. Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke. 2003;34:2000–2006
  66. Letechipía-Vallejo G, López-Loeza E, Espinosa-González V, et al. Long-term morphological and functional evaluation of the neuroprotective effects of post-ischemic treatment with melatonin in rats. J Pineal Res. 2007;42:139–146
  67. Fernandez-Lopez D, Pazos MR, Tolon RM, et al. The cannabinoid agonist WIN55212 reduces brain damage in an in vivo model of hypoxic–ischemic encephalopathy in newborns rats. Pediatr Res. 2007;62:255–260
  68. Alvarez FJ, Lafuente H, Rey-Santano MC, et al. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic–ischemic newborn piglets. Pediatr Res. 2008;64:653–658
  69. Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emergency theme of a deficiency in aspects of executive function. Neurotoxicol Teratol. 2001;23:1–11
  70. Ronen GM, Penney S, Andrews W. The epidemiology of clinical neonatal seizures in Newfoundland: a population-based study. J Pediatr. 1999;134:71–75
  71. Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med. 1999;341:485–489
  72. Dzhala VI, Talos DM, Sdrulla DA, et al. NKCC1 Transporter facilitates seizures in the developing brain. Nat Med. 2005;11:1205–1213
  73. Dzhala VI, Brumback AC, Staley KJ. Bumetanide enhances phenobarbital efficacy in a neonatal seizures model. Ann Neurol. 2008;63:222–235
  74. Bittigau P, Sifringer M, Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. Ann NY Acad Sci. 2003;993:103–114
  75. Olney JW, Wozniak DF, Jevtovic-Todorovic V, Farber NB, Bittigau P, Ikonomidou C. Drug-induced apoptotic neurodegeneration in the developing brain. Brain Pathol. 2002;12:488–498
  76. Stefovska VG, Uckermann O, Czuczwar M, et al. Sedative and anticonvulsant drugs suppress postnatal neurogenesis. Ann Neurol. 2008;64:434–445

    *The most important references are indicated with an asterisks.

PII: S1744-165X(10)00013-2

doi: 10.1016/j.siny.2010.02.002

Seminars in Fetal & Neonatal Medicine
Volume 15, Issue 5 , Pages 293-298 , October 2010

Article Tools